Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.60
Bid: 9.60
Ask: 10.00
Change: -0.15 (-1.54%)
Spread: 0.40 (4.167%)
Open: 9.55
High: 9.60
Low: 9.55
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of share options and Directors' dealings

23 Nov 2016 16:21

RNS Number : 9836P
e-Therapeutics plc
23 November 2016
 

23 November 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Grant of share options and Directors' dealings

 

Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total of 10,310,000 ordinary shares of 0.1p each to certain executive directors and other employees (the "Optionholders"). The Optionholders are entitled to exercise their options in three tranches (as set out below) on or after the date specified below, if, at the time of exercise, the prevailing market price of the Company's ordinary shares is not less than the price set out below (the "Exercise Price"). Optionholders will be required to pay the Exercise Price to exercise their options.

Number of shares under option Exercise Price Exercise Date

3,436,666 16.76p 23 November 2018

3,436,667 20.95p 23 November 2018

3,436,667 25.14p 23 November 2019

Details of the individual options granted to executive directors are set out below:

Director Number of shares under option

Steve Medlicott 2,000,000

Sean Nicolson 750,000

The options referred to above are otherwise subject to the Rules of the Company's 2013 Performance Share Plan. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Steve Medlicott

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Exercise price(s)

Volume(s)

 

£0.1676

666,666

 

 

£0.2095

666,667

 

 

£0.2514

666,667

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 2,000,000 options over ordinary shares

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

         

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Sean Nicolson

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

Exercise Price(s)

Volume(s)

 

£0.1676

250,000

 

 

£0.2095

250,000

 

 

£0.2514

250,000

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 750,000

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLRLTLVFIR
Date   Source Headline
12th Oct 20203:15 pmRNSHolding(s) in Company
12th Oct 20207:00 amRNSAppointment of Ali Mortazavi as CEO
12th Oct 20207:00 amRNSInterim Results for six months ended 31 July 2020
5th Oct 202012:07 pmRNSNotice of Interim Results
28th Sep 20207:00 amRNSExpansion of Scientific Advisory Board
28th Jul 20205:46 pmRNSHolding(s) in Company
23rd Jul 202010:03 amRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20205:55 pmRNSHolding(s) in Company
16th Jul 20207:01 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSDirector/PDMR Shareholding
15th Jul 20207:00 amRNSDirector/PDMR Shareholding
14th Jul 20204:49 pmRNSExercise of Broker Option and Total Fundraise
9th Jul 20204:47 pmRNSExercise of Broker Option
8th Jul 20204:41 pmRNSSecond Price Monitoring Extn
8th Jul 20204:36 pmRNSPrice Monitoring Extension
8th Jul 20202:05 pmRNSSecond Price Monitoring Extn
8th Jul 20202:00 pmRNSPrice Monitoring Extension
8th Jul 20207:00 amRNSResult of Retail Offer
7th Jul 20205:46 pmRNSRetail Offer
7th Jul 20205:42 pmRNSFundraise of up to £12.4 million
22nd Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20207:00 amRNSCollaboration with Galapagos
3rd Jun 20205:52 pmRNSHolding(s) in Company
2nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:36 pmRNSPrice Monitoring Extension
2nd Jun 20202:30 pmRNSResults of 2020 Annual General Meeting
28th May 20207:04 amRNSExpansion into RNAi and creation of SAB
18th May 20204:41 pmRNSSecond Price Monitoring Extn
18th May 20204:37 pmRNSPrice Monitoring Extension
18th May 202011:05 amRNSSecond Price Monitoring Extn
18th May 202011:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSExperimental testing initiated with WuXi AppTec
15th May 20205:17 pmRNSAnnual General Meeting – Change of Arrangement
15th May 20203:12 pmRNSe-therapeutics to present at Shares Evening
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 202011:05 amRNSSecond Price Monitoring Extn
16th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSAppointment of Chief Business Officer
23rd Mar 20207:00 amRNSAnti-viral drug discovery initiative
17th Mar 20207:00 amRNSResults for the year ended 31 January 2020
11th Mar 20201:30 pmRNSNotification of Full Year Results Date
20th Feb 20206:09 pmRNSHolding(s) in Company
18th Feb 202012:02 pmRNSHolding(s) in Company
11th Feb 202010:00 amRNSDirector/PDMR Shareholding
11th Feb 20207:00 amRNSBoard Changes and Placing
13th Jan 202012:58 pmRNSCorrection - Director/PDMR Shareholding
2nd Jan 20203:28 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.